Cargando…
PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430963/ http://dx.doi.org/10.1097/01.HS9.0000849904.09812.c6 |
| _version_ | 1784779922423676928 |
|---|---|
| author | Jabbour, E. Martinelli, G. Vignetti, M. Kantarjian, H. Gomez-Almaguer, D. Minami, Y. Dombret, H. Hennessy, M. Vorog, A. Wang, B. Ribera, J.-M. |
| author_facet | Jabbour, E. Martinelli, G. Vignetti, M. Kantarjian, H. Gomez-Almaguer, D. Minami, Y. Dombret, H. Hennessy, M. Vorog, A. Wang, B. Ribera, J.-M. |
| author_sort | Jabbour, E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430963 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94309632022-08-31 PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY Jabbour, E. Martinelli, G. Vignetti, M. Kantarjian, H. Gomez-Almaguer, D. Minami, Y. Dombret, H. Hennessy, M. Vorog, A. Wang, B. Ribera, J.-M. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430963/ http://dx.doi.org/10.1097/01.HS9.0000849904.09812.c6 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Jabbour, E. Martinelli, G. Vignetti, M. Kantarjian, H. Gomez-Almaguer, D. Minami, Y. Dombret, H. Hennessy, M. Vorog, A. Wang, B. Ribera, J.-M. PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY |
| title | PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY |
| title_full | PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY |
| title_fullStr | PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY |
| title_full_unstemmed | PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY |
| title_short | PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY |
| title_sort | pb1762: ponatinib versus imatinib with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome–positive (ph+) acute lymphoblastic leukemia (all): phallcon study |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430963/ http://dx.doi.org/10.1097/01.HS9.0000849904.09812.c6 |
| work_keys_str_mv | AT jabboure pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT martinellig pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT vignettim pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT kantarjianh pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT gomezalmaguerd pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT minamiy pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT dombreth pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT hennessym pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT voroga pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT wangb pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy AT riberajm pb1762ponatinibversusimatinibwithreducedintensitychemotherapyinpatientswithnewlydiagnosedphiladelphiachromosomepositivephacutelymphoblasticleukemiaallphallconstudy |